CYTOPEUTICS SDN. BHD.

Additional Information

Cytopeutics is the multi-award winning and trusted provider of mesenchymal stem cells (MSC) for clinical trials and treatment in the Asia-Pacific region. With nearly two decades of research and development, Cytopeutics is also at the forefront of research exploring the potential of multicellular immunotherapy, including cytokine-induced killer (CIK) cells and polarized M2 macrophages. Cytopeutics has completed several phase IIb/IIa pre-clinical programs with the cooperation of leading universities and hospitals locally and abroad. The programs are approved by ethical committees and national stem cell supervisory committees registered with US NIH. Cytopeutics is a pioneer Malaysian stem cell company granted with several USA Patents for acute stroke, diabetes and macular oedema treatment with cell-based composition, as well as local patents for treatment involving heart, stroke, diabetes, and autoimmune disease. The company has been granted clinical trial exemption (CTX) license to provide mesenchymal stem cells (Cyto-MSC) for clinical investigational use and processes stem cells under strict regulation, in-line with the International Pharmaceutical Inspection Cooperation Scheme (PIC/S) standards. Its processes are audited by the country’s Islamic authority ensuring that they meet a strict ethical compliance code and that the cells are cultured in animal-free medium. The company has a strong research collaboration with the Ministry of Health (MOH) and Institutes Of Higher Learning (LHL). Cytopeutics has been in the region for over 12 years on safety and efficacy with no complications. The clinicians and medical advisors are experts in the field of stem cells with many years of research experience and publications.